| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
FTRE
Fortrea Holdings Inc.
|
Oct 30, 2026 | BUY |
Buy
+8.3% avg upside
13 analysts
|
$28.00
31.61% Upside
|
-5.1% | Β· |
|
ALGN
Align Tech
|
Oct 30, 2026 | HOLD |
Buy
+89.9% avg upside
21 analysts
|
$165.00
10.01% Upside
|
+12.3% | Β· |
|
IQV
IQVIA Holdings
|
Oct 28, 2026 | BUY |
Strong Buy
-2.5% avg upside
40 analysts
|
$310.00
15.87% Upside
|
-5.0% | Β· |
|
ICLR
Icon
|
Oct 28, 2026 | BUY |
Strong Buy
-1.8% avg upside
28 analysts
|
$180.00
14.93% Downside
|
-9.1% | Β· |
|
HUM
Humana
|
Oct 13, 2026 | BUY |
Buy
+5.9% avg upside
34 analysts
|
$480.00
15.81% Upside
|
+5.5% | Β· |
|
UNH
UnitedHealth
|
Oct 13, 2026 | BUY |
Strong Buy
+12.6% avg upside
36 analysts
|
$480.00
18.03% Upside
|
+7.2% | Β· |
|
MCK
McKesson
|
Oct 06, 2026 | BUY |
Strong Buy
-20.4% avg upside
29 analysts
|
$1000.00
0.50% Upside
|
+19.7% | Β· |
|
CVS
CVS Health
|
Oct 02, 2026 | BUY |
Strong Buy
+19.5% avg upside
39 analysts
|
$125.00
38.57% Upside
|
+4.6% | Β· |
|
CI
Cigna
|
Oct 01, 2026 | HOLD |
Strong Buy
+15.7% avg upside
30 analysts
|
$290.00
2.78% Downside
|
+10.8% | Β· |
|
DOCS
Doximity
|
Sep 29, 2026 | HOLD |
Buy
+11.3% avg upside
28 analysts
|
$35.00
6.76% Upside
|
+25.7% | Β· |
|
CRL
Charles River Labs
|
Sep 25, 2026 | BUY |
Strong Buy
-28.5% avg upside
36 analysts
|
$330.00
8.23% Downside
|
+15.0% | Β· |
|
WAY
Waystar Holding Corp.
|
Sep 15, 2026 | BUY |
Strong Buy
+35.0% avg upside
30 analysts
|
$28.00
0.09% Downside
|
+6.8% | Β· |
|
LH
Labcorp Holdings
|
Sep 11, 2026 | BUY |
Strong Buy
-21.6% avg upside
38 analysts
|
$340.00
5.84% Downside
|
+19.5% | Β· |
|
OMDA
Omada Health, Inc.
|
Sep 11, 2026 | BUY |
Strong Buy
+46.6% avg upside
13 analysts
|
$25.00
33.47% Upside
|
-27.1% | Β· |
|
GMRS
GMR Solutions, Inc. Class A
|
Aug 13, 2026 | BUY |
Strong Buy
+66.5% avg upside
9 analysts
|
$20.00
78.64% Upside
|
-17.3% | Β· |
|
COR
Cencora
|
Aug 13, 2026 | BUY |
Strong Buy
-2.6% avg upside
45 analysts
|
$350.00
5.81% Upside
|
+16.3% | Β· |
|
CAH
Cardinal Health
|
Aug 12, 2026 | BUY |
Strong Buy
-14.3% avg upside
30 analysts
|
$270.00
7.87% Upside
|
+19.1% | Β· |
|
XRAY
DENTSPLY SIRONA
|
Aug 07, 2026 | HOLD |
Buy
+182.3% avg upside
25 analysts
|
$14.00
46.86% Upside
|
-22.1% | Β· |
|
NVST
Envista Holdings
|
Aug 06, 2026 | BUY |
Buy
+27.4% avg upside
19 analysts
|
$32.00
36.05% Upside
|
-10.6% | Β· |
|
MDLN
Medline
|
Aug 06, 2026 | BUY |
Strong Buy
+43.4% avg upside
27 analysts
|
$39.00
21.42% Upside
|
+14.4% | Β· |
|
PRVA
Privia Health Group
|
Aug 06, 2026 | BUY |
Strong Buy
+48.8% avg upside
26 analysts
|
$32.00
48.97% Upside
|
+11.6% | Β· |
|
AGL
Agilon Health
|
Aug 06, 2026 | HOLD |
Buy
-17.9% avg upside
26 analysts
|
$125.00
47.31% Upside
|
+33.2% | Β· |
|
HNGE
Hinge Health, Inc. Class A
|
Aug 04, 2026 | BUY |
Strong Buy
-8.2% avg upside
19 analysts
|
$105.00
8.22% Downside
|
+45.3% | Β· |
|
HSIC
Henry Schein
|
Aug 04, 2026 | BUY |
Buy
+9.6% avg upside
25 analysts
|
$105.00
23.78% Upside
|
-3.2% | Β· |
|
TDOC
Teladoc
|
Jul 30, 2026 | HOLD |
Buy
+241.7% avg upside
38 analysts
|
$7.50
11.90% Downside
|
+33.7% | Β· |
|
ELV
Elevance Health
|
May 19, 2026 | BUY |
Strong Buy
+10.7% avg upside
33 analysts
|
$360.00
14.26% Downside
|
+7.7% | Β· |
|
DGX
Quest Diagnostics
|
Apr 20, 2026 | HOLD |
Buy
-26.4% avg upside
34 analysts
|
$210.00
16.51% Downside
|
+32.7% | Β· |
|
HCAT
Health Catalyst
|
Mar 30, 2026 | HOLD |
Buy
+223.1% avg upside
15 analysts
|
$3.00
77.59% Upside
|
+21.2% | Β· |
|
EHTH
Ehealth
|
Aug 09, 2022 | HOLD |
Hold
+3096.7% avg upside
19 analysts
|
$8.50
1627.25% Upside
|
+18.9% | Β· |
|
SLQT
SelectQuote
|
May 06, 2022 | HOLD |
Hold
+2038.1% avg upside
16 analysts
|
$3.00
740.31% Upside
|
-47.7% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.